Immune Design to Present at Jefferies 2014 Global Healthcare Conference
November 13, 2014 08:00 ET
|
Immune Design Corp.
SEATTLE and SOUTH SAN FRANCISCO, Calif., Nov. 13, 2014 (GLOBE NEWSWIRE) -- Immune Design Corp. (Nasdaq:IMDZ), a clinical-stage immunotherapy company, today announced that Carlos Paya, M.D., Ph.D.,...
Immune Design Reports Third Quarter 2014 Financial Results and Provides Corporate Update
November 12, 2014 07:00 ET
|
Immune Design Corp.
SEATTLE and SOUTH SAN FRANCISCO, Calif., Nov. 12, 2014 (GLOBE NEWSWIRE) -- Immune Design Corp. (Nasdaq:IMDZ), a clinical-stage immunotherapy company, today reported financial results for the third...
Immune Design to Report Third Quarter 2014 Financial Results and Provide Corporate Update
November 05, 2014 08:00 ET
|
Immune Design Corp.
SEATTLE and SOUTH SAN FRANCISCO, Calif., Nov. 5, 2014 (GLOBE NEWSWIRE) -- Immune Design Corp. (Nasdaq:IMDZ), a clinical-stage immunotherapy company, today announced that it will report third quarter...
Sanofi Pasteur and Immune Design Enter Broad Collaboration for the Development of a Herpes Simplex Virus Therapy
October 16, 2014 08:00 ET
|
Immune Design Corp.
SEATTLE and SOUTH SAN FRANCISCO, Calif., Oct. 16, 2014 (GLOBE NEWSWIRE) -- Immune Design Corp. (Nasdaq:IMDZ), a clinical-stage immunotherapy company, today announced that it has entered into a broad...
Immune Design Added to Russell 2000(R) Index
October 02, 2014 08:00 ET
|
Immune Design Corp.
SEATTLE and SOUTH SAN FRANCISCO, Calif., Oct. 2, 2014 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ) announced today that the company was added to the Russell 2000® Index as part of Russell...
Sanofi Licenses Immune Design's GLAAS Platform to Explore Novel Approach to Treat Food Allergy
August 07, 2014 08:00 ET
|
Immune Design Corp.
CAMBRIDGE, Mass. and SEATTLE and SOUTH SAN FRANCISCO, Calif., Aug. 7, 2014 (GLOBE NEWSWIRE) -- Sanofi (EURONEXT:SAN) (NYSE:SNY) and Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company,...
Immune Design Announces Closing of Initial Public Offering
July 29, 2014 16:00 ET
|
Immune Design Corp.
SEATTLE and SOUTH SAN FRANCISCO, Calif., July 29, 2014 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ) announced today the closing of its initial public offering of 5,000,000 shares, at a public...
IMDZ Announces Filing of New Lawsuit by Theravectys SA
July 25, 2014 16:00 ET
|
Immune Design Corp.
SEATTLE and SOUTH SAN FRANCISCO, Calif., July 25, 2014 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ) announced today that the day after it began trading on the Nasdaq Global Market, Theravectys SA...
Immune Design Announces Pricing of Initial Public Offering
July 24, 2014 07:00 ET
|
Immune Design Corp.
SEATTLE and SOUTH SAN FRANCISCO, Calif., July 24, 2014 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ) announced today the pricing of its initial public offering of 5,000,000 shares of its common...
Immune Design Announces Treatment of First Patient in Phase 1 Clinical Trial of ID-G305 Cancer Immunotherapy Agent
February 27, 2014 08:00 ET
|
Immune Design Corp.
SEATTLE and SAN FRANCISCO, Feb. 27, 2014 (GLOBE NEWSWIRE) -- Immune Design, a clinical-stage immunotherapy company focused on the development of novel immune-based therapies for cancer and other...